Lipid management in chronic kidney disease, hemodialysis, and transplantation.Endocrinol Metab Clin North Am. 2009 Mar; 38(1):223-34.EM
Recent studies have shown the spectrum of dyslipidemia in patients who have chronic kidney disease (CKD) or end-stage renal disease to be different from that of the general population. This article discusses the pathophysiology of dyslipidemia in CKD, dialysis, and renal transplant patients, the therapeutic options, and their association with clinical outcomes. Whenever possible, comparisons are made to outcomes in the general population.